Αποτελέσματα αναζήτησης - "лекарственное лечение"

1

Academic Journal

Редкое клиническое наблюдение мономорфной эпителиотропной интестинальной Т-клеточной лимфомы

Πηγή: Клиническая онкогематология, Vol 18, Iss 3 (2025)

Θεματικοί όροι: лекарственное лечение, хирургическое лечение, мономорфная эпителиотропная интестинальная Т-клеточная лимфома, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

Σύνδεσμος πρόσβασης: https://doaj.org/article/5be81b21a76347db8623699f82864224

View record at OpenAIRE Full Text Finder

2

Academic Journal

Russian consensus on prevention, diagnosis and treatment of gastric cancer. Systemic therapy issues ; Российский консенсус по профилактике, диагностике и лечению рака желудка. Вопросы лекарственной терапии

Πηγή: Malignant tumours; Том 15, № 1 (2025); 76–85 ; Злокачественные опухоли; Том 15, № 1 (2025); 76–85 ; 2587-6813 ; 2224-5057

Θεματικοί όροι: системная химиотерапия, gastric cancer, systemic therapy, рак желудка, лекарственное лечение рака желудка

Περιγραφή αρχείου: application/pdf

Relation: https://www.malignanttumors.org/jour/article/view/1450/1037; Smyth E.C., Verheij M., Allum W., et al. ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2016;27(suppl 5):v38-v49. https://doi.org/10.1093/annonc/mdw350; Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2018 (5th edition). Gastric Cancer 2021;24(1):1–21. https://doi.org/10.1007/s10120-020-01041-y; NCCN Clinical Practice Guideline for Gastric Cancer version 3.2020. https://www.nccn.org/professionals/physician_gls/pdf/gastric.pdf; Guideline Committee of the Korean Gastric Cancer Association (KGCA), Development Working Group & Review Panel. Korean Practice Guideline for Gastric Cancer 2018: an Evidence-based, Multi-disciplinary Approach. J Gastric Cancer 2019;19(1):1–48. doi:10.5230/jgc.2019.19.e8. Epub 2019 Mar 19. Erratum in: J Gastric Cancer 2019 Sep;19(3):372–373; Polom K., Marano L., Marrelli D., et al. Meta-analysis of microsatellite instability in relation to clinicopathological characteristics and overall survival in gastric cancer. Br J Surg 2018;105(3):159–167. https://doi.org/10.1002/bjs.10663; Kim S.Y., Choi Y.Y., An J.Y., et al. The benefit of microsatellite instability is attenuated by chemotherapy in stage II and stage III gastric cancer: Results from a large cohort with subgroup analyses. Int J Cancer 2015;137(4):819–25. https://doi.org/10.1002/ijc.29449; Pietrantonio F., Miceli R., Raimondi A., et al. Individual patient data meta-analysis of the value of microsatellite instability as a biomarker in gastric cancer. J Clin Oncol 2019;37(35):3392–3400. https://doi.org/10.1200/JCO.19.01124; André T., Tougeron D., Piessen G., et al. Neoadjuvant nivolumab plus ipilimumab and adjuvant nivolumab in localized deficient mismatch repair/microsatellite instability-high gastric or esophagogastric junction adenocarcinoma: the GERCOR NEONIPIGA phase II study. J Clin Oncol 2023;41(2):255–265. https://doi.org/10.1200/JCO.22.00686; Pietrantonio F., Raimondi A., Lonardi S., et al. INFINITY: A multicentre, single-arm, multi-cohort, phase II trial of tremelimumab and durvalumab as neoadjuvant treatment of patients with microsatellite instability-high (MSI) resectable gastric or gastroesophageal junction adenocarcinoma (GAC/GEJAC). J Clin Oncol 2023;41(4): suppl 358. https://doi.org/10.1200/JCO.2023.41.4_suppl.358; Lorenzen S., Götze T.O., Thuss-Patience P., et al. Perioperative atezolizumab plus fluorouracil, leucovorin, oxaliplatin, and docetaxel for resectable esophagogastric cancer: interim results from the randomized, multicenter, phase II/III DANTE/IKF-s633 trial. J Clin Oncol 2024;42(4):410–420. https://doi.org/10.1200/JCO.23.00975; Sun H., Moiseyenko V., Chubenko V., et al. Neoadjuvant chemo-immunotherapy in mismatch repair deficient (dMMR)/ microsatellite instability (MSI) gastric carcinoma (GC): A multicenter retrospective study. Ann Oncol 2024;35(suppl_2):S180-S181. https://doi.org/10.1016/j.annonc.2024.05.362; Van Cutsem E., Moiseyenko V.M., Tjulandin S., et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol 2006;24(31):4991–7. https://doi.org/10.1200/JCO.2006.06.8429; Wang J., Xu R., Li J., et al. Randomized multicenter phase III study of a modified docetaxel and cisplatin plus fluorouracil regimen compared with cisplatin and fluorouracil as first-line therapy for advanced or locally recurrent gastric cancer. Gastric Cancer 2016;19(1):234–44. https://doi.org/10.1007/s10120-015-0457-4; Yamada Y., Boku N., Mizusawa J., et al. Docetaxel plus cisplatin and S-1 versus cisplatin and S-1 in patients with advanced gastric cancer (JCOG1013): an open-label, phase 3, randomised controlled trial. Lancet Gastroenterol Hepatol 2019;4(7):501–510. https://doi.org/10.1016/S2468-1253(19)30083-4; Guo X., Zhao F., Ma X., et al. A comparison between triplet and doublet chemotherapy in improving the survival of patients with advanced gastric cancer: a systematic review and meta-analysis. BMC Cancer 2019;19(1):1125. https://doi.org/10.1186/s12885-019-6294-9; Zaanan A., Bouche O., de la Fouchardiere C., et al. LBA77 5-fluorouracil and oxaliplatin with or without docetaxel in the first-line treatment of HER2 negative locally advanced (LA) unresectable or metastatic gastric or gastro-esophageal junction (GEJ) adenocarcinoma (GASTFOX-PRODIGE 51): A randomized phase III trial sponsored by the FFCD. Ann Oncol 2023;34(suppl_2):S1254-S1335. https://doi.org/10.1016/S0923-7534(23)04149-2; Ramaswamy A., Bhargava P., Dubashi B., et al. A two-arm randomized open-label prospective design superiority phase III clinical trial to compare the efficacy of docetaxel-oxaliplatin-capecitabine/5 fluorouracil (DOC/F) followed by docetaxel versus CAPOX/mFOLFOX-7 in advanced gastric cancers (DOC-GC study). J Clin Oncol 2024;42(3_suppl): LBA248-LBA248. https://doi.org/10.1200/JCO.2024.42.3_suppl.LBA248; Messager M., Lefevre J.H., Pichot-Delahaye V., et al. The impact of perioperative chemotherapy on survival in patients with gastric signet ring cell adenocarcinoma: a multicenter comparative study. Ann Surg 2011;254(5):684–93; https://doi.org/10.1097/SLA.0b013e3182352647; Sasako M., Sakuramoto S., Katai H., et al. Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. J Clin Oncol 2011;29(33):4387–93. https://doi.org/10.1200/JCO.2011.36.5908; Noh S.H., Park S.R., Yang H.K., et al. Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial. Lancet Oncol 2014;15(12):1389–96. https://doi.org/10.1016/S1470-2045(14)70473-5; Kozak K.R., Moody J.S. The survival impact of the intergroup 0116 trial on patients with gastric cancer. Int J Radiat Oncol Biol Phys 2008;72(2):517–21. https://doi.org/10.1016/j.ijrobp.2007.12.029; Ychou M., Boige V., Pignon J.P., et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol 2011;29(13):1715–21. https://doi.org/10.1200/JCO.2010.33.0597; Cunningham D., Allum W.H., Stenning S.P., et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006;355(1):11–20. https://doi.org/10.1056/NEJMoa055531; Al-Batran S.E., Homann N., Pauligk C., et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. Lancet 2019;393(10184):1948–1957. https://doi.org/10.1016/S0140-6736(18)32557-1; Lutz M.P., Zalcberg J.R., Ducreux M., et al. The 4th St. Gallen EORTC Gastrointestinal Cancer Conference: Controversial issues in the multimodal primary treatment of gastric, junctional and oesophageal adenocarcinoma. Eur J Cancer 2019;112:1–8. https://doi.org/10.1016/j.ejca.2019.01.106; Yoshida K., Kodera Y., Kochi M., et al. Addition of docetaxel to oral fluoropyrimidine improves efficacy in patients with stage III gastric cancer: interim analysis of JACCRO GC-07, a randomized controlled trial. J Clin Oncol 2019;37(15):1296–1304. https://doi.org/10.1200/JCO.18.01138; Park S.H., Zang D.Y., Han B., et al. ARTIST 2: Interim results of a phase III trial involving adjuvant chemotherapy and/ or chemoradiotherapy after D2-gastrectomy in stage II/III gastric cancer (GC). J Clin Oncol 2019;37(15_suppl):4001. https://doi.org/10.1200/jco.2019.37.15_suppl.4001; Allum W.H., Stenning S.P., Bancewicz J., et al. Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer. J Clin Oncol 2009;27(30):5062–5067. https://doi.org/10.1200/JCO.2009.22.2083; Al-Batran S. E, Homann N, Pauligk C., et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. Lancet 2019;393(10184):1948–1957. https://doi.org/10.1016/S0140-6736(18)32557-1; Van den Ende T., Veer E.T., Machiels M., et al. The efficacy and safety of (Neo)adjuvant therapy for gastric cancer: a network meta-analysis. Cancers (Basel) 2019;11(1):80. https://doi.org/10.3390/cancers11010080; Trumper M., Ross P.J., Cunningham D., et al. Efficacy and tolerability of chemotherapy in elderly patients with advanced oesophago-gastric cancer: A pooled analysis of three clinical trials. Eur J Cancer 2006;42(7):827–34. https://doi.org/10.1016/j.ejca.2005.08.044; Jatoi A., Foster N.R., Egner J.R., et al. Older versus younger patients with metastatic adenocarcinoma of the esophagus, gastroesophageal junction, and stomach: a pooled analysis of eight consecutive North Central Cancer Treatment Group (NCCTG) trials. Int J Oncol 2010;36(3):601–6. https://doi.org/10.3892/ijo_00000535; Hall P.S., Lord S.R., Collinson M., et al. A randomised phase II trial and feasibility study of palliative chemotherapy in frail or elderly patients with advanced gastroesophageal cancer (321GO). Br J Cancer 2017;116(4):472–478. https://doi.org/10.1038/bjc.2016.442; Hwang I.G., Ji J.H., Kang J.H., et al. A multi-center, open-label, randomized phase III trial of first-line chemotherapy with capecitabine monotherapy versus capecitabine plus oxaliplatin in elderly patients with advanced gastric cancer. J Geriatr Oncol 2017;8(3):170–175. https://doi.org/10.1016/j.jgo.2017.01.002; Hall P.S., Swinson D., Cairns D.A., et al. Efficacy of reduced-intensity chemotherapy with oxaliplatin and capecitabine on quality of life and cancer control among older and frail patients with advanced gastroesophageal cancer: the GO2 phase 3 randomized clinical trial. JAMA Oncol 2021;7(6):869–877. https://doi.org/10.1001/jamaoncol.2021.0848; Thuss-Patience P.C., Kretzschmar A., Bichev D., et al. Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer--a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). Eur J Cancer 2011;47(15):2306–14. https://doi.org/10.1016/j.ejca.2011.06.002; Ford H.E., Marshall A., Bridgewater J.A., et al. Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial. Lancet Oncol 2014;15(1):78–86. https://doi.org/10.1016/S1470-2045(13)70549-7; Hironaka S., Ueda S., Yasui H., et al. Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 trial. J Clin Oncol 2013;31(35):4438–44. https://doi.org/10.1200/JCO.2012.48.5805; Wilke H., Muro K., Van Cutsem E., et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastrooesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol 2014;15(11):1224–1235. https://doi.org/10.1016/S1470-2045(14)70420-6; Kaya A.O., Coskun U., Gumus M., et al. The efficacy and toxicity of irinotecan with leucovorin and bolus and continuous infusional 5-fluorouracil (FOLFIRI) as salvage therapy for patients with advanced gastric cancer previously treated with platinum and taxane-based chemotherapy regimens. J Chemother 2012;24(4):217–20. https://doi.org/10.1179/1973947812Y.0000000020; Maugeri-Saccà M., Pizzuti L., Sergi D., et al. FOLFIRI as a second-line therapy in patients with docetaxel-pretreated gastric cancer: a historical cohort. J Exp Clin Cancer Res 2013;32(1):67. https://doi.org/10.1186/1756-9966-32-67; Sendur M.A., Ozdemir N., Özatlı T., et al. Comparison the efficacy of second-line modified EOX (epirubicin, oxaliplatin, and capecitabine) and irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) regimens in metastatic gastric cancer patients that progressed on first-line modified docetaxel and cisplatin plus fluorouracil (DCF) regimen. Med Oncol 2014;31(9):153. https://doi.org/10.1007/s12032-014-0153-y; Jung J.Y., Ryu M.H., Ryoo B.Y., et al. Second-line irinotecan, leucovorin, and 5-fluorouracil for gastric cancer patients after failed docetaxel and S-1. Gastroenterol Res Pract 2016;2016:6857625. https://doi.org/10.1155/2016/6857625; Klempner S.J., Maron S.B., Chase L., et al. Initial report of second-line FOLFIRI in combination with ramucirumab in advanced gastroesophageal adenocarcinomas: a multi-institutional retrospective analysis. Oncologist 2019;24(4):475–482. https://doi.org/10.1634/theoncologist.2018-0602; Бесова Н.С., Титова Т.А., Строяковский Д.Л. и соавт. Результаты применения рамуцирумаба с иринотеканом и фторпиримидинами во второй линии лечения больных диссеминированным раком желудка. Медицинский совет 2019;10:100–109. https://doi.org/10.21518/2079-701X-2019-10-100-109; Lorenzen S., Thuss-Patiens P., Pauligk C., et al. FOLFIRI plus ramucirumab versus paclitaxel plus ramucirumab for patients with advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction as second-line therapy: Interim safety and efficacy results from the phase II RAMIRIS Study (AIO-STO-0415) of the German Gastric Group at AIO. Journal of Clinical Oncology 38(15_suppl):4514–4514. https://doi.org/10.1200/JCO.2020.38.15suppl.4514; Sym S.J., Hong J., Park J., et al. A randomized phase II study of biweekly irinotecan monotherapy or a combination of irinotecan plus 5-fluorouracil/leucovorin (mFOLFIRI) in patients with metastatic gastric adenocarcinoma refractory to or progressive after first-line chemotherapy. Cancer Chemother Pharmacol 2013;71(2):481–8. https://doi.org/10.1007/s00280-012-2027-3; Tanabe K., Fujii M., Nishikawa K., et al. Phase II/III study of second-line chemotherapy comparing irinotecan-alone with S-1 plus irinotecan in advanced gastric cancer refractory to first-line treatment with S-1 (JACCRO GC-05). Ann Oncol 2015;26(9):1916–1922. https://doi.org/10.1093/annonc/mdv265; Shitara K., Özgüroğlu M., Bang Y.J., et al. Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial. Lancet 2018;392(10142):123–133. https://doi.org/10.1016/S0140-6736(18)31257-1; Chao J., Fuchs C.S., Shitara K., et al. Assessment of pembrolizumab therapy for the treatment of microsatellite instability-high gastric or gastroesophageal junction cancer among patients in the KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 clinical trials. JAMA Oncol 2021;7(6):895–902. https://doi.org/10.1001/jamaoncol.2021.0275.; https://www.malignanttumors.org/jour/article/view/1450

Διαθεσιμότητα: https://www.malignanttumors.org/jour/article/view/1450
https://doi.org/10.18027/2224-5057-2025-036

View record from BASE

3

Academic Journal

Studying the effect of high-protein nutritional support on postoperative outcomes and during adjuvant chemotherapy in patients with primary gastric cancer ; Изучение влияния высокобелковой нутритивной поддержки на послеоперационные исходы и в процессе адъювантной химиотерапии у больных первичным раком желудка

Συγγραφείς: M. N. Khagazheeva, A. V. Snegovoy, A. M. Kelemetov, V. O. Tatyanin, N. M. Starostin, М. Н. Хагажеева, А. В. Снеговой, А. М. Келеметов, В. О. Татьянин, Н. М. Старостин

Πηγή: Meditsinskiy sovet = Medical Council; № 22 (2023); 110-120 ; Медицинский Совет; № 22 (2023); 110-120 ; 2658-5790 ; 2079-701X

Θεματικοί όροι: специализированные продукты лечебного питания, surgical treatment, chemotherapy, drug treatment, postoperative complications, symptomatic therapy, nutritional status, protein nutrition, oral nutritional supplements, хирургическое лечение, химиотерапия, лекарственное лечение, послеоперационные осложнения, симптоматическая терапия, нутритивный статус, высокобелковое питание

Περιγραφή αρχείου: application/pdf

Relation: https://www.med-sovet.pro/jour/article/view/7998/7087; Durán Poveda M, Suárez-de-la-Rica A, Cancer Minchot E, Ocón Bretón J, Sánchez Pernaute A, Rodríguez Caravaca G. The Prevalence and Impact of Nutritional Risk and Malnutrition in Gastrointestinal Surgical Oncology Patients: A Prospective, Observational, Multicenter, and Exploratory Study. Nutrients. 2023;15(14):3283. https://doi.org/10.3390/nu15143283.; Arends J, Bachmann P, Baracos V, Barthelemy N, Bertz H, Bozzetti F et al. ESPEN guidelines on nutrition in cancer patients. Clin Nutr. 2017;36(1):11–48. https://doi.org/10.1016/j.clnu.2016.07.015.; Baldwin C, Spiro A, Ahern R, Emery PW. Oral nutritional interventions in malnourished patients with cancer: a systematic review and meta-analysis. J Natl Cancer Inst. 2012;104(5):371–385. https://doi.org/10.1093/jnci/djr556.; Ravasco P, Monteiro-Grillo I, Camilo M. Individualized nutrition intervention is of major benefit to colorectal cancer patients: long-term follow-up of a randomized controlled trial of nutritional therapy. Am J Clin Nutr. 2012;96(6):1346–1353. https://doi.org/10.3945/ajcn.111.018838.; Baracos VE. Cancer-associated malnutrition. Eur J Clin Nutr. 2018;72(9):1255–1259. https://doi.org/10.1038/s41430-018-0245-4.; Guenter P, Abdelhadi R, Anthony P, Blackmer A, Malone A, Mirtallo JM et al. Malnutrition diagnoses and associated outcomes in hospitalized patients: United States, 2018. Nutr Clin Pract. 2021;36(5):957–969. https://doi.org/10.1002/ncp.10771.; Brown T, Edwards A, Pashley A, Lehn B, Vasani S, Hodge R, Bauer J. Nutritional status and post-operative complications in patients undergoing surgery for advanced pharyngeal or laryngeal cancer. Eur Arch Otorhinolaryngol. 2023;280(12):5531–5538. https://doi.org/10.1007/s00405-023-08139-x.; Shpata V, Prendushi X, Kreka M, Kola I, Kurti F, Ohri I. Malnutrition at the time of surgery affects negatively the clinical outcome of critically ill patients with gastrointestinal cancer. Med Arch. 2014;68(4):263–267. https://doi.org/10.5455/medarh.2014.68.263-267.; Bossi P, Delrio P, Mascheroni A, Zanetti M. The Spectrum of Malnutrition/ Cachexia/Sarcopenia in Oncology According to Different Cancer Types and Settings: A Narrative Review. Nutrients. 2021;13(6):1980. https://doi.org/10.3390/nu13061980.; Хомяков ВМ, Хороненко ВЭ, Ермошина АД. Проблема нутритивной недостаточности и методы ее коррекции у больных со злокачественными опухолями пищевода и желудка. Онкология. Журнал им. П.А. Герцена. 2016;5(5):33–37. https://doi.org/10.17116/onkolog20165533-37.; Снеговой АВ, Бесова НС, Веселов АВ, Кравцов СА, Ларионова ВБ, Сельчук ВЮ и др. Практические рекомендации по нутритивной поддержке у онкологических больных. Злокачественные опухоли. 2016;(4s2):434–450. Режим доступа: https://rosoncoweb.ru/standarts/RUSSCO/2016/40.pdf.; Jie B, Jiang ZM, Nolan MT, Zhu SN, Yu K, Kondrup J. Impact of preoperative nutritional support on clinical outcome in abdominal surgical patients at nutritional risk. Nutrition. 2012;28(10):1022–1027. https://doi.org/10.1016/j.nut.2012.01.017.; Cederholm T, Jensen GL, Correia MITD, Gonzalez MC, Fukushima R, Higashiguchi T et al. GLIM criteria for the diagnosis of malnutrition – A consensus report from the global clinical nutrition community. Clin Nutr. 2019;38(1):1–9. https://doi.org/10.1016/j.clnu.2018.08.002.; Лейдерман ИН, Грицан АИ, Заболотских ИБ, Ломидзе СВ, Мазурок ВА, Нехаев ИВ и др. Периоперационная нутритивная поддержка. Клинические рекомендации. Вестник интенсивной терапии имени А.И. Салтанова. 2018;(3):5–21. https://doi.org/10.21320/1818-474X-2018-3-5-21.; Weimann A, Braga M, Carli F, Higashiguchi T, Hübner M, Klek S et al. ESPEN guideline: Clinical nutrition in surgery. Clin Nutr. 2017;36(3):623–650. https://doi.org/10.1016/j.clnu.2017.02.013.; Mortensen K, Nilsson M, Slim K, Schäfer M, Mariette C, Braga M et al. Consensus guidelines for enhanced recovery after gastrectomy: Enhanced Recovery After Surgery (ERAS®) Society recommendations. Br J Surg. 2014;101(10):1209–1229. https://doi.org/10.1002/bjs.9582.; Li Z, Bai B, Zhao Y, Yu D, Lian B, Liu Y, Zhao Q. Severity of complications and long-term survival after laparoscopic total gastrectomy with D2 lymph node dissection for advanced gastric cancer: A propensity score-matched, case-control study. Int J Surg. 2018;54(Pt A):62–69. https://doi.org/10.1016/j.ijsu.2018.04.034.; Самсонов МА, Покровский АА (ред.). Справочник по диетологии. 2-е изд. М.: Медицина; 1992. 464 с.; Fearon K, Strasser F, Anker SD, Bosaeus I, Bruera E, Fainsinger RL et al. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol. 2011;12(5):489–495. https://doi.org/10.1016/S1470-2045(10)70218-7.; Wang LH, Zhu RF, Gao C, Wang SL, Shen LZ. Application of enhanced recovery after gastric cancer surgery: An updated meta-analysis. World J Gastroenterol. 2018;24(14):1562–1578. https://doi.org/10.3748/wjg.v24.i14.1562.; Obukhova O, Kashiya S, Kurmukov I. MON-P100: Metabolic Disorders in Patients with Advanced Gastric Cancer before Antitumor Chemotherapy. Clin Nutr. 2017;36(Suppl. 1):S216. https://doi.org/10.1016/S0261-5614(17)30983-4.; Тер-Ованесов МД, Кукош МЮ, Габоян АС, Левицкий АВ, Зраибиа А. Концепция ускоренной реабилитации в хирургическом лечении рака пищевода и желудка: постановка проблемы. Медицинский алфавит. 2017;1(16):17–22. Режим доступа: https://www.med-alphabet.com/jour/article/view/147.; Cantwell LA, Fahy E, Walters ER, Patterson JM. Nutritional prehabilitation in head and neck cancer: a systematic review. Support Care Cancer. 2022;30(11):8831–8843. https://doi.org/10.1007/s00520-022-07239-4.; Горбунова ЕА, Филькин ГН, Медведева НН, Зуков РА. Влияние энтерального питания на клиническое течение послеоперационного периода у больных раком желудка. Эффективная фармакотерапия. 2021;17(2):30–36. Режим доступа: https://umedp.ru/articles/vliyanie_enteralnogo_pitaniya_na_klinicheskoe_techenie_posleoperatsionnogo_perioda_u_bolnykh_rakom_zh.html.; West MA, Wischmeyer PE, Grocott MPW. Prehabilitation and Nutritional Support to Improve Perioperative Outcomes. Curr Anesthesiol Rep. 2017;7(4):340–349. https://doi.org/10.1007/s40140-017-0245-2.

Διαθεσιμότητα: https://www.med-sovet.pro/jour/article/view/7998
https://doi.org/10.21518/ms2023-455

View record from BASE

4

Academic Journal

Pembrolizumab in treatment of head and neck squamous cell carcinoma: clinical cases and real-world practice ; Пембролизумаб в лечении плоскоклеточного рака головы и шеи: клинические исследования и реальная практика

Συγγραφείς: Yu. V. Alymov, I. S. Romanov, A. V. Ignatova, Ю. В. Алымов, И. С. Романов, А. В. Игнатова

Συνεισφορές: The publication was prepared with the sponsorship of BIOCAD., Публикация подготовлена при спонсорской поддержке компании BIOCAD.

Πηγή: Head and Neck Tumors (HNT); Том 13, № 2 (2023); 35-43 ; Опухоли головы и шеи; Том 13, № 2 (2023); 35-43 ; 2411-4634 ; 2222-1468 ; 10.17650/2222-1468-2023-13-2

Θεματικοί όροι: плоскоклеточный рак, drug treatment, pembrolizumab, pembroria, carcinoma, head and neck, squamous cell carcinoma, лекарственное лечение, пембролизумаб, пемброриа, карцинома, голова и шея

Περιγραφή αρχείου: application/pdf

Relation: https://ogsh.abvpress.ru/jour/article/view/887/584; Злокачественные новообразования в России в 2017 году (заболеваемость и смертность). Под ред. А.Д. Каприна, В.В. Старинского, Г.В. Петровой. М.: МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2018; El-Naggar A.K., Chan J.K.C., Grandis J.R., Slootweg P.J. WHO classification of head and neck tumours. 2017. Available at: https://publications.iarc.fr/Book-And-Report-Series/Who-Classification-Of-Tumours/WHO-Classification-Of-Head-And-Neck-Tumours-2017; Sanderson R.J., Ironside J.A. Squamous cell carcinomas of the head and neck. BMJ 2002;325(7368):822–7. DOI:10.1136/bmj.325.7368.822; Pignon J.P., le Maître A., Maillard E., Bourhis J. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother Oncol 2009;92(91):4–14. DOI:10.1016/j.radonc.2009.04.014; Bernier J., Domenge C., Ozsahin M. et al. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med 2004;350:1945–52. DOI:10.1056/NEJMoa032641; Cooper J.S., Pajak T.F., Forastiere A.A. et al. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med 2004;350(19):1937–44. DOI:10.1056/NEJMoa032646; Reeves T.D., Hill E.G., Armeson K.E., Gillespie M.B. Cetuximab therapy for head and neck squamous cell carcinoma: a systematic review of the data. Otolaryngol Head Neck Surg 2011;144(5):676–84. DOI:10.1177/0194599811399559; Jacobs C., Lyman G., Velez-García E. et al. A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck. J Clin Oncol 1992;10(2):257–63. DOI:10.1200/JCO.19; Grau J.J., Caballero M. et al. Weekly paclitaxel for platin-resistant stage IV head and neck cancer patients. Acta Otolaryngol 2009;129(11):1294–9. DOI:10.3109/00016480802590451; Catimel G., Verweij J., Mattijssen V. et al. Docetaxel (Taxotere®): An active drug for the treatment of patients with advanced squamous cell carcinoma of the head and neck. Ann Oncol 1994;5(6):533–7. DOI:10.1093/oxfordjournals.annonc.a058908; Guardiola E., Peyrade F., Chaigneau L. et al. Results of a randomised phase II study comparing docetaxel with methotrexate in patients with recurrent head and neck cancer. Eur J Cancer 2004;40(14):2071–6. DOI:10.1016/j.ejca.2004.05.019; Martinez-Trufero J., Isla D., Adansa J.C. et al. Phase II study of capecita-bine as palliative treatment for patients with recurrent and metastatic squamous head and neck cancer after previous platinum-based treatment. Br J Cancer 2010;102(12):1687–91. DOI:10.1038/sj.bjc.6605697; Guntinas-Lichius O., Appenrodt S., Veelken F., Krug B. Phase II study of weekly docetaxel and cisplatin in patients with advanced recurrent and metastatic head and neck cancer. Laryngoscope 2006;116(4):613–8. DOI:10.1097/01.mlg.0000208366.34683.58; Gibson M.K., Li Y., Murphy B. et al. Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): an intergroup trial of the Eastern Cooperative Oncology Group. J Clin Oncol 2005;23(15):3562–7. DOI:10.1200/JCO.2005.01.057; Vermorken J.B., Mesia R., Rivera F. et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 2008;359(11):1116–27. DOI:10.1056/NEJMoa0802656; Grandis J., Tweardy D. Elevated levels of transforming growth factor α and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer. Cancer Res 1993;53(15):3579–84.; Baselga J., Trigo J.M., Bourhis J. et al. Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck. J Clin Oncol 23(24):5568–77. DOI:10.1200/JCO.2005.07.119; Herbst R.S., Arquette M., Shin D.M. et al. Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck. J Clin Oncol 2005;23(24):5578–87. DOI:10.1200/JCO.2005.07.120; Vermorken J.B., Trigo J., Hitt R. et al. Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. J Clin Oncol 2007;25(16):2171–7. DOI:10.1200/JCO.2006.06.7447; León X., Hitt R., Constenla M. et al. A retrospective analysis of the outcome of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck refractory to a platinum-based chemotherapy. Clin Oncol (R Coll Radiol) 2005;17(6):418–24. DOI:10.1016/j.clon.2005.02.014; Guigay J., Fayette J., Mesia R. et al. TPExtreme randomized trial: TPEx versus extreme regimen in 1st line recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC). J Clin Oncol 2019;37(15):6002.; Badoual C., Hans S., Merillon N. et al. PD-1-expressing tumor-infiltrating T cells are a favorable prognostic biomarker in HPV-associated head and neck cancer. Cancer Res 2013;73(1):128–38. DOI:10.1158/0008-5472.CAN-12-2606; Zandberg D.P., Strome S.E. The role of the PD-L1: PD-1 pathway in squamous cell carcinoma of the head and neck. Oral Oncol 2014;50:627–32. DOI:10.1016/j.oraloncology.2014.04.003; Cohen E.E.W., Soulières D., Le Tourneau C. et al. Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study. Lancet 2019;393(10167):156–67. DOI:10.1016/S0140-6736(18)31999-8; Harrington K.J., Soulières D., Le Tourneau C. et al. Quality of Life with pembrolizumab for recurrent and/or metastatic head and neck squamous cell carcinoma: KEYNOTE-040. J Natl Cancer Inst 2021;113(2):171–81. DOI:10.1093/jnci/djaa063; Soulieres D., Harrington K.J., Le Tourneau C. et al. 658MO Pembro lizumab (pembro) vs standard-of-care (SOC) in previously treated recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): 6-year follow-up of KEYNOTE-040. Ann Oncol 2022; 33(7):S843.; Burtness B., Harrington K.J., Greil R. et al. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet 2019;23;394(10212):1915–28. DOI:10.1016/S0140-6736(19)32591-7; Rischin D., Harrington K.J., Greil R. et al. Protocol-specified final analysis of the phase 3 KEYNOTE-048 trial of pembrolizumab (pembro) as first-line therapy for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC). J Clin Oncol 2019;37(Suppl. 15):6000. DOI:10.1200/JCO.2019.37.15_suppl.6000; Harrington K.J., Burtness B., Greil R. et al. Pembrolizumab with or without chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma: updated results of the phase III KEYNOTE-048 study. J Clin Oncol 2023;41(4):790–802. DOI:10.1200/JCO.21.02508; Tahara M., Greil R., Rischin D. et al. 659MO Pembrolizumab with or without chemotherapy for first-line treatment of recurrent/ metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): 5-year results from KEYNOTE-048. Ann Oncol 2022;33(Suppl. 7): S295–322. DOI:10.1016/annonc/annonc1056; Chen W.C., Chu P.Y., Lee Y.T. et al. Pembrolizumab for recurrent/ metastatic head and neck squamous cell carcinoma in an Asian population. Medicine (Baltimore) 2017;96(52):e9519. DOI:10.1097/MD.0000000000009519; He Y., Zeng J., Wei Z. et al. Comparison of second-line treatments for patients with platinum-resistant recurrent or metastatic head and neck squamous cell carcinoma: a systematic review and bayesian network meta-analysis. Cancers (Basel) 2022;14(18):4472. DOI:10.3390/cancers14184472; Wagner S.M., Magnes T., Melchardt T. et al. Real-world data of palliative first-line checkpoint inhibitor therapy for head and neck cancer. Anticancer Res 2023;43(3):1273–82. DOI:10.21873/anticanres.16274; Sano D., Tokuhisa M., Takahashi H. et al. Real-world therapeutic outcomes of the pembrolizumab regimen as first-line therapy for recurrent/metastatic squamous cell carcinoma of the head and neck: a single-center retrospective cohort study in Japan. Anticancer Res 2022;42(9):4477–84. DOI:10.21873/anticanres.15948; Болотина Л.В., Владимирова Л.Ю., Деньгина Н.В. и др. Практические рекомендации по лечению злокачественных опухолей головы и шеи. Злокачественные опухоли: Практические рекомендации RUSSCO #3s2. 2022;12:94–112.; https://ogsh.abvpress.ru/jour/article/view/887

Διαθεσιμότητα: https://ogsh.abvpress.ru/jour/article/view/887
https://doi.org/10.17650/2222-1468-2023-13-2-35-43

View record from BASE

5

Academic Journal

Russian consensus on prevention, diagnosis and treatment of gastric cancer ; Российский консенсус по профилактике, диагностике и лечению рака желудка

Συγγραφείς: I. E. Khatkov, S. R. Abdulkhakov, S. A. Alekseenko, I. D. Amelina, D. N. Andreev, E. V. Artamonova, N. V. Bakulina, N. S. Besova, L. V. Bolotina, D. S. Bordin, O. S. Vasnev, L. Yu. Vladimirova, Z. V. Galkova, B. I. Dolgushin, L. G. Zhukova, E. O. Ignatova, R. E. Izrailov, V. A. Isakov, A. E. Kalinin, A. M. Karachun, G. G. Karmazanovskii, S. V. Kashin, V. A. Kachenko, V. A. Kim, P. V. Kononets, L. N. Kostyuchenko, T. N. Kuzmina, Yu. V. Kulezneva, S. A. Kurilovich, Yu. A. Kucheryavii, M. A. Livzan, V. K. Lyadov, I. V. Maev, O. A. Malikhova, B. M. Medvedeva, V. M. Moiseenko, S. V. Morozov, I. Yu. Nedolugko, M. F. Osipenko, E. V. Parfenchikova, V. D. Pasechnikov, S. S. Pirogov, I. A. Pokataev, S. A. Protcenko, A. B. Ryabov, N. E. Semenov, E. N. Solodinina, Yu. G. Starkov, I. S. Stilidi, D. L. Stroyakovskii, O. B. Tkachenko, A. A. Tryakin, S. А. Tjulandin, А. А. Fedenko, M. Yu. Fedyanin, S. G. Homeriki, V. M. Homyakov, V. V. Tsvirkun, V. V. Tsukanov, L. N. Shevkunov, K. V. Shishin, V. V. SHCHadrova, Yu. V. Embutnieks, И. Е. Хатьков, С. Р. Абдулхаков, С. А. Алексеенко, И. Д. Амелина, Д. Н. Андреев, Е. В. Артамонова, Н. В. Бакулина, Н. С. Бесова, Л. В. Болотина, Д. С. Бордин, О. С. Васнев, Л. Ю. Владимирова, З. В. Галкова, Б. И. Долгушин, Л. Г. Жукова, Е. О. Игнатова, Р. Е. Израилов, В. А. Исаков, А. Е. Калинин, А. М. Карачун, Г. Г. Кармазановский, С. В. Кашин, В. А. Кащенко, В. А. Ким, П. В. Кононец, Л. Н. Костюченко, Т. Н. Кузьмина, Ю. В. Кулезнева, С. А. Курилович, Ю. А. Кучерявый, М. А. Ливзан, В. К. Лядов, И. В. Маев, О. А. Малихова, Б. М. Медведева, В. М. Моисеенко, С. В. Морозов, И. Ю. Недолужко, М. Ф. Осипенко, Е. В. Парфенчикова, В. Д. Пасечников, С. С. Пирогов, И. А. Покатаев, С. А. Проценко, А. Б. Рябов, Н. Е. Семенов, Е. Н. Солодинина, Ю. Г. Старков, И. С. Стилиди, Д. Л. Строяковский, О. Б. Ткаченко, А. А. Трякин, С. А. Тюляндин, А. А. Феденко, М. Ю. Федянин, С. Г. Хомерики, В. М. Хомяков, В. В. Цвиркун, В. В. Цуканов, Л. Н. Шевкунов, К. В. Шишин, В. В. Щадрова, Ю. В. Эмбутниекс

Πηγή: Malignant tumours; Том 13, № 2 (2023); 56-68 ; Злокачественные опухоли; Том 13, № 2 (2023); 56-68 ; 2587-6813 ; 2224-5057

Θεματικοί όροι: скрининг и профилактика рака желудка, gastric cancer prevention, gastric cancer diagnosis, gastric cancer treatment, рак желудка, хирургическое лечение рака желудка, инструментальная диагностика рака желудка, лекарственное лечение рака желудка

Περιγραφή αρχείου: application/pdf

Relation: https://www.malignanttumors.org/jour/article/view/1091/787; Hamashima C; Systematic Review Group and Guideline Development Group for Gastric Cancer Screening Guidelines. Update version of the Japanese Guidelines for Gastric Cancer Screening. Jpn J Clin Oncol. 2018 Jul 1; 48 (7) : 673-683. doi:10.1093/jjco/hyy077. PMID: 29889263.; Qiu H, Zhou Z. [Updates and interpretation on NCCN clinical practice guidelines for gastric cancer 2017 version 5]. Zhonghua Wei Chang Wai Ke Za Zhi. 2018 Feb 25; 21 (2) : 160-164. PMID: 29492914.; Smyth EC, Verheij M, Allum W, Cunningham D, Cervantes A, Arnold D; ESMO Guidelines Committee. Gastric cancer : ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016 Sep; 27 (suppl 5) : v38-v49. doi:10.1093/annonc/mdw350. PMID: 27664260.; Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2018 (5th edition). Gastric Cancer. 2021 Jan; 24 (1) : 1-21. doi:10.1007/s10120-020-01042-y. Epub 2020 Feb 14. PMID: 32060757; PMCID: PMC7790804.; Методические рекомендации по оценке достоверности доказательств и убедительности рекомендаций. ФЕДЕРАЛЬНОЕ ГОСУДАРСТВЕННОЕ БЮДЖЕТНОЕ УЧРЕЖДЕНИЕ «Центр экспертизы и контроля качества медицинской помощи» Министерства здравоохранения Российской Федерации (ФГБУ «ЦЭККМП» Минздрава России»). 2017.; Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE : an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008; 336 : 924-6.; Guyatt GH, Oxman AD, Kunz R, Falck-Ytter Y, Vist GE, Liberati A, et al. Going from evidence to recommendations. BMJ 2008; 336 : 1049-51.; Sultan S, Falck-Ytter Y, Inadomi JM. The AGA institute process for developing clinical practice guidelines part one : grading the evidence. Clin Gastroenterol Hepatol 2013; 11 : 329-32.; https://www.malignanttumors.org/jour/article/view/1091

Διαθεσιμότητα: https://www.malignanttumors.org/jour/article/view/1091
https://doi.org/10.18027/2224-5057-2023-13-2-4

View record from BASE

6

Academic Journal

Effects of nutritional support in cancer patients receiving chemotherapy ; Эффекты нутритивной поддержки, проводимой при лекарственном противоопухолевом лечении пациентов онкологического профиля

Συγγραφείς: Galeeva E.V., Stepanova A.M., Kostin A.A.

Πηγή: Head and Neck Tumors; Vol 11, No 4 (2021); 50-57 ; Опухоли головы и шеи; Vol 11, No 4 (2021); 50-57 ; 2411-4634 ; 2222-1468

Θεματικοί όροι: drug treatment, nutritional support, clinical nutrition, enteral nutrition, treatment outcomes, nutritional support in oncology, лекарственное лечение, нутритивная поддержка, клиническое питание, энтеральное питание, исходы лечения, нутритивная поддержка в онкологии

Περιγραφή αρχείου: application/pdf

Relation: https://ogsh.abvpress.ru/jour/article/view/715/502; https://ogsh.abvpress.ru/jour/article/view/715

Διαθεσιμότητα: https://ogsh.abvpress.ru/jour/article/view/715
https://doi.org/10.17650/2222-1468-2021-11-4-50-57

View record from BASE

7

Academic Journal

Survival of patients with metastatic bladder cancer in the Russian Federation: results of a multicenter registry study URRU ; Продолжительность жизни больных метастатическим раком мочевого пузыря в Российской Федерации: результаты многоцентрового регистрового исследования URRU

Πηγή: Cancer Urology; Том 17, № 3 (2021); 102-109 ; Онкоурология; Том 17, № 3 (2021); 102-109 ; 1996-1812 ; 1726-9776

Θεματικοί όροι: продолжительность жизни, urothelial carcinoma, pharmacotherapy, chemotherapy, cancer immunology, registry, survival, уротелиальный рак, лекарственное лечение, химиотерапия, иммуноонкология, регистр

Περιγραφή αρχείου: application/pdf

Relation: https://oncourology.abvpress.ru/oncur/article/view/1520/1303; Злокачественные новообразования в России в 2017 году (заболеваемость и смертность). Под ред. А.Д. Каприна, В.В. Старинского, Г.В. Петровой. М.: МНИОИ им. ПА. Герцена - филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2018. 250 с.; Гладков О.А., Матвеев В.Б., Митин Т. и др. Практические рекомендации по лекарственному лечению рака мочевого пузыря. Злокачественные опухоли: Практические рекомендации RUSSCO #3s2, 2020;10(3s2):32. DOI:10.18027/2224-5057-2020-10-3s2-32.; Senkus-Konefka E., Lajos G., Drumea K. et al. Challenges and recommendations for real-world evidence in oncology: focus on Central and Eastern Europe. eCancer, 2021. Available at: https://ecancer.org/en/news/21108-challenges-and-recommendations-for-real-world-evidence-in-oncology-focus-on-central-and-eastern-europe.; Минаков С.Н., Левина Ю.В., Простов М.Ю. Популяционный раковый регистр. Функциональные возможности, задачи и существующие проблемы. Злокачественные опухоли 2019;9(1):6-9. DOI:10.18027/2224-5057-2019-9-1-6-9.; Simeone J.C., Nordstrom B.L., Patel K. et al. Treatment patterns and overall survival in metastatic urothelial carcinoma in a real-world, US setting. Cancer Epidemiol 2019;60:121-7. DOI:10.1016/j.canep.2019.03.013.; Omland L.H., Lindberg H., Carus A. et al. Real-world treatment patterns and overall survival in locally advanced and metastatic urothelial tract cancer patients treated with chemotherapy in Denmark in the preimmunotherapy era: a nationwide, population-based study. Eur Urol Open Sci 2020;24:1-8. DOI:10.1016/j.euros.2020.12.002.; Niegisch G., Gerullis H., Lin S.W. et al. A real-world data study to evaluate treatment patterns, clinical characteristics and survival outcomes for first-and second-line treatment in locally advanced and metastatic urothelial cancer patients in Germany. J Cancer 2018;9(8): 1337-48. DOI:10.7150/jca.23162.; Bilen M.A., Xi A.D., Wong A. et al. Real-world (RW) treatment (Tx) patterns and clinical outcomes in patients (pts) with metastatic urothelial carcinoma (mUC) receiving first-line (1L) Tx: Results from IMPACT UC. Ann Oncol 2021;32(suppl_5):S678-724. DOI:10.1016/annonc/annonc675.; Ramaswamy A., Joshi A., Noronha V. et al. Patterns of care and clinical outcomes in pati-ents with metastatic renal cell carcinoma-results from a tertiary cancer center in India. Clin Genitourin Cancer 2017;15(3):e345-55. DOI:10.1016/j.clgc.2016.09.006.; Bergerot P.G., Bergerot C.D., Dizman N. et al. Assessment of treatment patterns for metastatic renal cell carcinoma in Brazil. J Glob Oncol 2018;4:1-8. DOI:10.1200/JGO.17.00113.; Powles T., Park S.H., Voog E. et al. Avelumab maintenance therapy for advanced or meta-static urothelial carcinoma. N Engl J Med 2020;383(13):1218—30. DOI:10.1056/NEJMoa2002788.; https://oncourology.abvpress.ru/oncur/article/view/1520

Διαθεσιμότητα: https://oncourology.abvpress.ru/oncur/article/view/1520
https://doi.org/10.17650/1726-9776-2021-17-3-102-109

View record from BASE

8

Academic Journal

IMPACT OF THE COVID-19 PANDEMIC ON THE ONCOLOGICAL PRACTICE ; ВЛИЯНИЕ ПАНДЕМИИ COVID-19 НА ОНКОЛОГИЧЕСКУЮ ПРАКТИКУ

Συγγραφείς: A. D. Kaprin, E. V. Gameeva, A. A. Polyakov, A. L. Kornietskaya, N. A. Rubtsova, A. A. Fedenko, А. Д. Каприн, Е. В. Гамеева, А. А. Поляков, А. Л. Корниецкая, Н. А. Рубцова, А. А. Феденко

Πηγή: Siberian journal of oncology; Том 19, № 3 (2020); 5-22 ; Сибирский онкологический журнал; Том 19, № 3 (2020); 5-22 ; 2312-3168 ; 1814-4861 ; 10.21294/1814-4861-2020-19-3

Θεματικοί όροι: солидные опухоли, SARS-CoV-2, pandemic, oncology, drug treatment of tumors, oncohematology, solid tumors, пандемия, онкология, лекарственное лечение опухолей, онкогематология

Περιγραφή αρχείου: application/pdf

Relation: https://www.siboncoj.ru/jour/article/view/1483/742; Guan W.J., Ni Z.Y., Hu Y., Liang W.H., Ou C.Q., He J.X., Liu L., Shan H., Lei C.L., Hui D.S.C., Du B., Li L.J., Zeng G., Yuen K.Y., Chen R.C., Tang C.L., Wang T., Chen P.Y., Xiang J., Li S.Y., Wang J.L., Liang Z.J., Peng Y.X., Wei L., Liu Y., Hu Y.H., Peng P., Wang J.M., Liu J.Y., Chen Z., Li G., Zheng Z.J., Qiu S.Q., Luo J., Ye C.J., Zhu S.Y., Zhong N.S.; China Medical Treatment Expert Group for COVID-19. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020; 382(18): 1708–20. doi:10.1056/NEJMoa2002032.; Li Q., Guan X., Wu P., Wang X., Zhou L., Tong Y., Ren R., Leung K.S.M., Lau E.H.Y., Wong J.Y., Xing X., Xiang N., Wu Y., Li C., Chen Q., Li D., Liu T., Zhao J., Liu M., Tu W., Chen C., Jin L., Yang R., Wang Q., Zhou S., Wang R., Liu H., Luo Y., Liu Y., Shao G., Li H., Tao Z., Yang Y., Deng Z., Liu B., Ma Z., Zhang Y., Shi G., Lam T.T.Y., Wu J.T., Gao G.F., Cowling B.J., Yang B., Leung G.M., Feng Z. Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia. N Engl J Med. 2020 Mar 26; 382(13): 1199–1207. doi:10.1056/NEJMoa2001316.; Chen N., Zhou M., Dong X., Qu J., Gong F., Han Y., Qiu Y., Wang J., Liu Y., Wei Y., Xia J., Yu T., Zhang X., Zhang L. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020 Feb 15; 395(10223): 507–513. doi:10.1016/S0140-6736(20)30211-7.; Holshue M.L., DeBolt C., Lindquist S., Lofy K.H., Wiesman J., Bruce H., Spitters C., Ericson K., Wilkerson S., Tural A., Diaz G., Cohn A., Fox L., Patel A., Gerber S.I., Kim L., Tong S., Lu X., Lindstrom S., Pallansch M.A., Weldon W.C., Biggs H.M., Uyeki T.M., Pillai S.K.; Washington State 2019-nCoV Case Investigation Team. First Case of 2019 Novel Coronavirus in the United States. N Engl J Med. 2020 Mar 5; 382(10): 929–936. doi:10.1056/NEJMoa2001191.; Huang C., Wang Y., Li X., Ren L., Zhao J., Hu Y., Zhang L., Fan G., Xu J., Gu X., Cheng Z. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The Lancet. 2020; 395(10223): 497–506. doi:10.1016/S0140-6736(20)30183-5.; Wang D., Hu B., Hu C., Zhu F., Liu X., Zhang J., Wang B., Xiang H., Cheng Z., Xiong Y., Zhao Y., Li Y., Wang X., Peng Z. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA. 2020; 323(11): 1061–9. doi:10.1001/jama.2020.1585.; Chan J.F., Yuan S., Kok K.H., To K.K., Chu H., Yang J., Xing F., Liu J., Yip C.C., Poon R.W., Tsoi H.W., Lo S.K., Chan K.H., Poon V.K., Chan W.M., Ip J.D., Cai J.P., Cheng V.C., Chen H., Hui C.K., Yuen K.Y. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet. 2020 Feb 15; 395(10223): 514–523. doi:10.1016/S0140-6736(20)30154-9.; Hoehl S., Rabenau H., Berger A., Kortenbusch M., Cinatl J., Bojkova D., Behrens P., Böddinghaus B., Götsch U., Naujoks F., Neumann P., Schork J., Tiarks-Jungk P., Walczok A., Eickmann M., Vehreschild M.J.G.T., Kann G., Wolf T., Gottschalk R., Ciesek S. Evidence of SARS-CoV-2 Infection in Returning Travelers from Wuhan, China. N Engl J Med. 2020 Mar 26; 382(13): 1278–1280. doi:10.1056/NEJMc2001899.; Wang H., Zhang L. Risk of COVID-19 for patients with cancer. Lancet Oncol. 2020 Apr; 21(4): e181. doi:10.1016/S1470-2045(20)30149-2.; You B., Ravaud A., Canivet A., Ganem G., Giraud P., Guimbaud R., Kaluzinski L., Krakowski I., Mayeur D., Grellety T., Lotz J.P. The official French guidelines to protect patients with cancer against SARS-CoV-2 infection. Lancet Oncol. 2020; 21(5): 619–21. doi:10.1016/S1470-2045(20)30204-7.; Liang W., Guan W., Chen R., Wang W., Li J., Xu K., Li C., Ai Q., Lu W., Liang H., Li S., He J. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol. 2020 Mar; 21(3): 335–337. doi:10.1016/S1470-2045(20)30096-6.; Burki T.K. Cancer care in the time of COVID-19. Lancet Oncol. 2020 May; 21(5): 628. doi:10.1016/S1470-2045 (20)30201-1.; Burki T.K. Cancer guidelines during the COVID-19 pandemic. Lancet Oncol. 2020 May; 21(5): 629–630. doi:10.1016/S1470-2045(20)30217-5.; Wang Z., Wang J., He J. Active and Effective Measures for the Care of Patients With Cancer During the COVID-19 Spread in China. JAMA Oncol. 2020; 6(5): 631632. doi:10.1001/jamaoncol.2020.1198.; ESMO. Cancer patient management during the COVID-19 pandemic [Internet]. URL: https://www.esmo.org/guidelines/cancer-patientmanagement-during-the-COVID-19-pandemic?hit=ehp&page=1 (cited 01.04.2020).; Miyashita H., Mikami T., Chopra N., Yamada T., Chernyavsky S., Rizk D., Cruz C. Do patients with cancer have a poorer prognosis of COVID-19? An experience in New York City. Ann Oncol. 2020 Apr 21: S09237534(20)39303-0. doi:10.1016/j.annonc.2020.04.006.; Временные методические рекомендации: профилактика, диагностика и лечение новой коронавирусной инфекции (COVID-19) [Интернет]. URL: https://static1.rosminzdrav.ru/system/attachments/attaches/000/050/116/original/28042020_%D0%9CR_COVID-19_v6.pdf (дата обращения: 01.04.2020).; I of the WHO-China Joint Mission on Coronavirus Disease 2019 (COVID-19) [Internet]. URL: https://www.who.int/publications-detail/report-of-the-who-china-joint-mission-on-coronavirus-disease-2019-(COVID-19) (cited 01.04.2020).; Mehta V., Goel S., Kabarriti R., Cole D., Goldfinger M., Acuna-Villaorduna A., Pradhan K., Thota R., Reissman S., Sparano J.A., Gartrell B.A., Smith R.V., Ohri N., Garg M., Racine A.D., Kalnicki S., Perez-Soler R., Halmos B., Verma A. Case Fatality Rate of Cancer Patients with COVID-19 in a New York Hospital System. Cancer Discov. 2020 May 1: CD-20-0516. doi:10.1158/2159-8290.CD-20-0516.; Wang M., Cao R., Zhang L., Yang X., Liu J., Xu M., Shi Z., Hu Z., Zhong W., Xiao G. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020 Mar; 30(3): 269–271. doi:10.1038/s41422-020-0282-0.; Metlay J.P., Waterer G.W., Long A.C., Anzueto A., Brozek J., Crothers K., Cooley L.A., Dean N.C., Fine M.J., Flanders S.A., Griffin M.R., Metersky M.L., Musher D.M., Restrepo M.I., Whitney C.G. Diagnosis and Treatment of Adults with Community-acquired Pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America. Am J Respir Crit Care Med. 2019 Oct 1; 200(7): e45e67. doi:10.1164/rccm.201908-1581ST.; Russell C.D., Millar J.E., Baillie J.K. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. The Lancet. 2020; 395(10223): 473–475. doi:10.1016/S0140-6736(20)30317-2.; Поддубная И.В., Сычев Д.А. Особенности ведения онкологических пациентов во время пандемии коронавирусной инфекции COVID-19 [Интернет]. URL: https://rosoncoweb.ru/news/COVID-19/2020/04/07-2/module.pdf (дата обращения: 01.04.2020).; Hung I.F., Lung K.C., Tso E.Y., Liu R., Chung T.W., Chu M.Y., Ng Y.Y., Lo J ., Chan J., Tam A.R., Shum H.P., Chan V., Wu A.K., Sin K.M., Leung W.S., Law W.L., Lung D.C., Sin S., Yeung P., Yip C.C., Zhang R.R., Fung A.Y., Yan E.Y., Leung K.H., Ip J.D., Chu A.W., Chan W.M., Ng A.C., Lee R., Fung K., Yeung A., Wu T.C., Chan J.W., Yan W.W., Chan W.M., Chan J.F., Lie A.K., Tsang O.T., Cheng V.C., Que T.L., Lau C.S., Chan K.H., To K.K., Yuen K.Y. Triple combination of interferon beta-1b, lopinavirritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial. Lancet. 2020 May 30; 395(10238): 1695–1704. doi:10.1016/S0140-6736(20)31042-4.; COVID-19: Elective Case Triage Guidelines for Surgical Care. American College of Surgeons. March 24, 2020. https://www.facs.org/COVID-19/clinical-guidance/elective-case/.; Mayor S. COVID-19: impact on cancer workforce and delivery of care. Lancet Oncol. 2020 May; 21(5): 633. doi:10.1016/S1470- 2045(20)30240-0.; Simcock R., Thomas T.V., Estes C., Filippi A.R., Katz M.A., Pereira I.J., Saeed H. COVID-19: Global radiation oncology’s targeted response for pandemic preparedness. Clin Transl Radiat Oncol. 2020 Mar 24; 22: 55–68. doi:10.1016/j.ctro.2020.03.009.; Профилактика, диагностика и лечение новой коронавирусной инфекции (COVID-19) у онкологических больных [Интернет]. URL: https://oncology-association.ru/files/pdf/2020/COVID.pdf (дата обращения: 01.04.2020).; ESMO management and treatment adapted recommendations in the COVID-19 era: primary brain tumours [Internet]. URL: https://www.esmo.org/guidelines/cancer-patient-management-during-the-COVID19-pandemic/primary-brain-tumours-in-the-COVID-19-era (cited: 01.04.2020).; ESMO management and treatment adapted recommendations in the COVID-19 era: diffuse large B-cell lymphoma, mantle cell lymphoma and aggressive T-cell lymphomas [Internet]. URL: https://www.esmo.org/guidelines/cancer-patient-management-during-the-COVID-19-pandemic/haematological-malignancies-dlbcl-mcl-and-aggressive-t-cell-lymphomain-the-COVID-19-era (cited: 01.04.2020).; ESMO management and treatment adapted recommendations in the COVID-19 era: multiple myeloma [Internet]. URL: https://www.esmo.org/guidelines/cancer-patient-management-during-the-COVID-19-pandemic/haematological-malignancies-multiple-myeloma-in-the-COVID-19-era (cited: 01.04.2020).; ESMO management and treatment adapted recommendations in the COVID-19 era: breast cancer [Internet]. URL: https://www.esmo.org/guidelines/cancer-patient-management-during-the-COVID-19-pandemic/breast-cancer-in-the-COVID-19-era (cited: 01.04.2020).; ESMO management and treatment adapted recommendations in the COVID-19 era: colorectal cancer [Internet]. URL: https://www.esmo.org/guidelines/cancer-patient-management-during-the-COVID-19-pandemic/gastrointestinal-cancers-colorectal-cancer-crc-in-the-COVID-19-era (cited: 01.04.2020).; ESMO management and treatment adapted recommendations in the COVID-19 era: renal cell cancer [Internet]. URL: https://www.esmo.org/guidelines/cancer-patient-management-during-the-COVID-19-pandemic/genitourinary-cancers-renal-cell-cancer-in-the-COVID-19-era (cited: 01.04.2020).; ESMO management and treatment adapted recommendations in the COVID-19 era: prostate cancer [Internet]. URL: https://www.esmo.org/guidelines/cancer-patient-management-during-the-COVID-19- pandemic/genitourinary-cancers-prostate-cancer-in-the-COVID-19-era (cited: 01.04.2020).; ESMO management and treatment adapted recommendations in the COVID-19 era: epithelial ovarian cancer [Internet]. URL: https://www.esmo.org/guidelines/cancer-patient-management-during-the-COVID-19-pandemic/gynaecological-malignancies-epithelial-ovarian-cancer-in-theCOVID-19-era (cited: 01.04.2020).; ESMO management and treatment adapted recommendations in the COVID-19 era: melanoma [Internet]. URL: https://www.esmo.org/guidelines/cancer-patient-management-during-the-COVID-19-pandemic/melanoma-in-the-COVID-19-era (cited: 01.04.2020).; Penel N., Bonvalot S., Minard V., Orbach D., Gouin F., Corradini N., Brahmi M., Marec-Bérard P., Briand S., Gaspar N., Llacer C., Carrère S., Dufresne A., Le Cesne A., Blay J.Y. French Sarcoma Group proposals for management of sarcoma patients during the COVID-19 outbreak. Ann Oncol. 2020 Apr 9; 31(7): 965–966. doi:10.1016/j.annonc.2020.03.308.; Bersanelli M. Controversies about COVID-19 and anticancer treatment with immune checkpoint inhibitors. Immunotherapy. 2020 Apr; 12(5): 269–273. doi:10.2217/imt-2020-0067.; Mei H., Dong X., Wang Y., Tang L., Hu Y. Managing patients with cancer during the COVID-19 pandemic: frontline experience from Wuhan. Lancet Oncol. 2020 May; 21(5): 634–636. doi:10.1016/S1470- 2045(20)30238-2.; Главный внештатный онколог Минздрава: рак не уходит на карантин [Интернет]. URL: https://tass.ru/interviews/8391689 (дата обращения: 01.04.2020).; Геращенко Я.Л. Обзор клинических рекомендаций по ведению пациентов с подтвержденной коронавирусной болезнью (COVID-19) выпущенных Американским национальным центром иммунизации и респираторных заболеваний (NCIRD). Русский медицинский журнал [Интернет]. URL: https://www.rmj.ru/articles/infektsiya/obzorklinicheskikh-rekomendatsiy-po-vedeniyu-patsientov-s-podtverzhdennoykoronavirusnoy-boleznyu-COVID-19-vypushchennykh-amerikanskimnatsionalnym-tsentrom-immunizatsii-i-respiratornykh-zabolevaniy-ncird/ (дата обращения: 01.04.2020).; https://www.siboncoj.ru/jour/article/view/1483

Διαθεσιμότητα: https://www.siboncoj.ru/jour/article/view/1483
https://doi.org/10.21294/1814-4861-2020-19-3-5-22

View record from BASE

9

Academic Journal

Life expectancy in patients with metastatic renal cell carcinoma in the Russian Federation: results of the RENSUR3 multicenter registry study ; Продолжительность жизни больных метастатическим почечно-клеточным раком в Российской Федерации: результаты многоцентрового регистрового исследования RENSUR3

Πηγή: Malignant tumours; Том 9, № 2 (2019); 45-52 ; Злокачественные опухоли; Том 9, № 2 (2019); 45-52 ; 2587-6813 ; 2224-5057

Θεματικοί όροι: продолжительность жизни, drug therapy, targeted therapy, immuno-oncology, registry, life expectancy, лекарственное лечение, таргетная терапия, иммуноонкология, регистр

Περιγραφή αρχείου: application/pdf

Relation: https://www.malignanttumors.org/jour/article/view/637/440; Kaprin A, Starinskiy V, Petrova G. Malignant tumors in Russia in 2015 (morbidity and mortality). Moscow. 2017. p.250. ISBN 978-5-85502-227-8; Tsimafeyeu I, Aksel E. Renal Cell Carcinoma in the Russian Federation in 2008. Malign Tumours 1 (2010): 1-4.; NCCN Clinical Practice Guidelines in Oncology: Kidney Cancer, version 1.2015.; Tsimafeyeu I, Zart JS, Chung B. Cytoreductive radiofrequency ablation in patients with metastatic renal cell carcinoma (RCC) with small primary tumours treated with sunitinib or interferon-a. BJU International 112 (1), 32-38.; НосовД.А.,ВоробьевН.А., ГладковО.А., ссоавт. Практические рекомендации по лекарственному лечению почечноклеточного рака. Злокачественные опухоли. 2015. — № 4, спецвыпуск. — C.281-285. doi: 10/18027/2224-5057-2015-4s-281-285; Минаков С.Н., Левина Ю.В., Простов М.Ю. Популяционный раковый регистр. Функциональные возможности, задачи и существующие проблемы. Злокачественные опухоли. 2019;9 (1):6—9. doi:10.18027/2224-5057-2019-9-1-6-9; Состояние онкологической помощи населению России в 2017 году (под ред. А.Д. Каприна, В.В. Старинского, Г.В. Петровой) М.: МНИОИ им. П.А. Герцена филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2018.-илл. 236 с. ISBN 978-5-85502-237-7; Ramaswamy A, Joshi A, Noronha V, et al. Patterns of Care and Clinical Outcomes in Patients With Metastatic Renal Cell Carcinoma-Results From a Tertiary Cancer Center in India. ClinGenitourin Cancer. 2017 Jun;15 (3):e345-e355.; Coelho RC, Reinert T, Campos F, et al. Sunitinib treatment in patients with advanced renal cell cancer: the Brazilian National Cancer Institute (INCA) experience. IntBraz J Urol. 2016 Jul-Aug;42 (4):694-703.; Nurgaliev N, Kaidarova D, Shatkovskaya O, et al. Real-world outcomes in patients with metastatic renal cell carcinoma in Kazakhstan. Presented at the Fourteenth Annual European International Kidney Cancer Symposium, 2019.; Kim JK, Kim SH, Song MK, et al. Application of the International Metastatic Renal Cell Carcinoma Database Consortium and Memorial Sloan Kettering Cancer Center Risk Models in Patients with Metastatic Non-Clear Cell Renal Cell Carcinoma: A Multi-Institutional Retrospective Study Using the Korean Metastatic Renal Cell Carcinoma Registry. Cancer Res Treat.2018 Sep 7. doi:10.4143/crt.2018.421. [Epub ahead of print].; Poprach A, Lakomy R, Bortlicek Z, et al. Efficacy of Sunitinib in Elderly Patients with Metastatic Renal Cell Carcinoma: Data from Real-World Clinical Practice. Drugs Aging. 2016 Sep;33 (9):655-63.; Bergerot PG, Bergerot CD, Dizman N, et al. Assessment of Treatment Patterns for Metastatic Renal Cell Carcinoma in Brazil. J Glob Oncol. 2018 Sep;4:1-8.; Boegemann M, Hubbe M, Thomaidou D, et al. Sunitinib Treatment Modification in First-Line Metastatic Renal Cell Carcinoma: Analysis of the STAR-TOR Registry. Anticancer Res. 2018 Nov;38 (11):6413-6422.; Finek J, Demlova R, Kopeckova K, et al. Treatment sequences in metastatic renal cell carcinoma: Efficacy results from the Czech registry (RENIS). Annals of Oncology, Volume 29, Issue suppl_8, October 2018, mdy283.101, https://doi.org/10.1093/annonc/mdy283.101; Rini BI, de La Motte Rouge T, Harzstark AL, et al. Five-year survival in patients with cytokine-refractory metastatic renal cell carcinoma treated with axitinib. ClinGenitourin Cancer. 2013 Jun;11 (2):107-14.; Tsimafeyeu I, Borisov P, Abdelgafur A, et al. Phase 2 Multicenter Single-Arm Study of Second-Line Axitinib in Favorable Risk Patients with Metastatic Renal Cell Carcinoma: FavorAx. Target Oncol. 2019 Feb;14 (1):33—38.; McDermott DF, Motzer RJ, Atkins MB, et al. Long-term overall survival (OS) with nivolumab in previously treated patients with advanced renal cell carcinoma (aRCC) from phase I and II studies. J ClinOncol 34, 2016 (suppl; abstr 4507).; Albiges L, Negrier S, Dalban C, et al. Safety and efficacy of nivolumab in metastatic renal cell carcinoma (mRCC): Final analysis from the NIVOREN GETUG AFU 26 study. J ClinOncol 37, 2019 (suppl 7S; abstr 542).; De Giorgi U, Carteni G, Giannarelli D, et al. Safety and efficacy of nivolumab for metastatic renal cell carcinoma: real-world results from an expanded access programme. BJU Int. 2019 Jan;123 (1):98-105.; Motzer RJ, Escudier B, McDermott DF, et al. Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med. 2015 Nov 5;373 (19):1803-13.; Sharma P. et al. 16th International Kidney Cancer Symposium; November 3-4, 2017; Miami, FL, USA.; Rao A, Wiggins C, Lauer RC. Survival outcomes for advanced kidney cancer patients in the era of targeted therapies. Ann Transl Med. 2018 May;6 (9):165.; Tsimafeyeu I, Zolotareva T, Varlamov S, et al. Five-year overall survival among patients with metastatic renal cell carcinoma: Results of Russian population-based study RENSUR5. J ClinOncol 35, 2017 (suppl 5S; abstr 20).; Tsimafeyeu I, Zolotareva T, Varlamov S, et al. Five-year Survival of Patients With Metastatic Renal Cell Carcinoma in the Russian Federation: Results From the RENSUR5 Registry. ClinGenitourinCancer. 2017 Dec;15 (6):e1069-e1072.; Li P, Jahnke J, Pettit AR, Wong YN, Doshi JA. Comparative Survival Associated With Use of Targeted vs Nontargeted Therapy in Medicare Patients With Metastatic Renal Cell Carcinoma. JAMA Netw Open. 2019 Jun 5;2 (6):e195806.; Shteynshlyuger A. Many Elderly Patients With Stage IV Metastatic Renal Cell Carcinoma May Benefit From More-Aggressive Treatment. JAMA Netw Open. 2019 Jun 5;2 (6):e195815.; https://www.malignanttumors.org/jour/article/view/637

Διαθεσιμότητα: https://www.malignanttumors.org/jour/article/view/637
https://doi.org/10.18027/2224-5057-2019-9-2-45-52

View record from BASE

10

Academic Journal

Drug treatment for metastatic breast cancer

Συγγραφείς: E. V. Artamonova

Πηγή: Опухоли женской репродуктивной системы, Vol 0, Iss 4, Pp 46-53 (2014)

Θεματικοί όροι: метастатический рак молочной железы, лекарственное лечение, гормональная терапия, химиотерапия, Gynecology and obstetrics, RG1-991

Περιγραφή αρχείου: electronic resource

Relation: https://ojrs.abvpress.ru/ojrs/article/view/196; https://doaj.org/toc/1994-4098; https://doaj.org/toc/1999-8627

Σύνδεσμος πρόσβασης: https://doaj.org/article/e75c1cc63e4a4c04a29118e03661566b

View record in DOAJ Full Text Finder

11

Academic Journal

Лечение несветлоклеточного почечно-клеточного рака

Συγγραφείς: PEETER PADRIK

Πηγή: Malignant tumours; Том 1, № 1 (2011); 40-44 ; Злокачественные опухоли; Том 1, № 1 (2011); 40-44 ; 2587-6813 ; 2224-5057

Θεματικοί όροι: лекарственное лечение, несветлоклеточный рак почки, хирургическое лечение

Περιγραφή αρχείου: application/pdf

Relation: https://www.malignanttumors.org/jour/article/view/143/148; Gupta K, Miller JD, Li JZ, Russell MW, Charbonneau C. Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): a literature review. Cancer Treat Rev. 2008 May;34(3):193-205.; Reuter VE, Presti JC, Jr. Contemporary approach to the classification of renal epithelial tumors. Semin Oncol. 2000 Apr;27(2):124-37.; Reuter VE. The pathology of renal epithelial neoplasms. Semin Oncol. 2006 Oct;33(5):534-43.; Beck SD, Patel MI, Snyder ME, Kattan MW, Motzer RJ, Reuter VE, et al. Effect of papillary and chromophobe cell type on disease-free survival after nephrectomy for renal cell carcinoma. Ann Surg Oncol. 2004 Jan;11(1):71-7.; Patard JJ, Leray E, Rioux-Leclercq N, Cindolo L, Ficarra V, Zisman A, et al. Prognostic value of histologic subtypes in renal cell carcinoma: a multicenter experience. J Clin Oncol. 2005 Apr 20;23(12):2763-71.; Motzer RJ, Bacik J, Mariani T, Russo P, Mazumdar M, Reuter V. Treatment outcome and survival associated with metastatic renal cell carcinoma of non-clear-cell histology. J Clin Oncol. 2002 May 1;20(9):2376-81.; Ronnen EA, Kondagunta GV, Ishill N, Spodek L, Russo P, Reuter V, et al. Treatment outcome for metastatic papillary renal cell carcinoma patients. Cancer. 2006 Dec 1;107(11):2617-21.; Ljungberg B, Cowan NC, Hanbury DC, Hora M, Kuczyk MA, Merseburger AS, et al. EAU guidelines on renal cell carcinoma: the 2010 update. Eur Urol. 2010 Sep;58(3):398-406.; Flanigan RC, Mickisch G, Sylvester R, Tangen C, Van Poppel H, Crawford ED. Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis. J Urol. 2004 Mar;171(3):1071-6.; Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Staehler M, et al. Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol. 2009 Jul 10;27(20):3312-8.; Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. The New England journal of medicine. 2007 Jan 11;356(2):115-24.; Escudier B, Pluzanska A, Koralewski P, Ravaud A, Bracarda S, Szczylik C, et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet. 2007 Dec 22;370(9605):2103-11.; Sternberg CN, Davis ID, Mardiak J. Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial. J Clin Oncol. 2010;28(6):1061-8.; Rini BI, Halabi S, Rosenberg JE, Stadler WM, Vaena DA, Ou SS, et al. Bevacizumab Plus Interferon Alfa Compared With Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: CALGB 90206. J Clin Oncol. 2008 Oct 20.; Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, et al. Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors. Cancer. Jun 14.; Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. The New England journal of medicine. 2007 May 31;356(22):2271-81.; Dutcher JP, de Souza P, McDermott D, Figlin RA, Berkenblit A, Thiele A, et al. Effect of temsirolimus versus interferon-alpha on outcome of patients with advanced renal cell carcinoma of different tumor histologies. Med Oncol. 2009;26(2):202-9.; Gordon MS, Hussey M, Nagle RB, Lara PN, Jr., Mack PC, Dutcher J, et al. Phase II study of erlotinib in patients with locally advanced or metastatic papillary histology renal cell cancer: SWOG S0317. J Clin Oncol. 2009 Dec 1;27(34):5788-93.; Gore ME, Szczylik C, Porta C, Bracarda S, Bjarnason GA, Oudard S, et al. Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial. Lancet Oncol. 2009 Aug;10(8):757-63.; Ravaud A, et al. First-line sunitinib in type I and II papillary renal cell carcinoma (PRCC): SUPAP, a phase II study of the French Genito-Urinary Group (GETUG) and the Group of Early Phase trials (GEP). J Clin Oncol (Meeting Abstr) 2009 27: 5146. 2009.; Plimack E, et al. Sunitinib in papillary renal cell carcinoma (pRCC): Results from a single-arm phase II study. J Clin Oncol (Meeting Abstr) 2010, 28:4604. 2010.; Molina AM, Feldman DR, Ginsberg MS, Kroog G, Tickoo SK, Jia X, et al. Phase II trial of sunitinib in patients with metastatic non-clear cell renal cell carcinoma. Invest New Drugs. 2010 Aug 14.; Stadler W, et al. The Advanced Renal Cell Carcinoma Sorafenib (ARCCS) expanded access trial: Safety and efficacy in patients (pts) with non-clear cell (NCC) renal cell carcinoma (RCC). J Clin Oncol (Meeting Abstracts) 2007 25, 5036. 2007.; Choueiri TK, Plantade A, Elson P, Negrier S, Ravaud A, Oudard S, et al. Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma. J Clin Oncol. 2008 Jan 1;26(1):127-31.; Oevermann K, Buer J, Hoffmann R, Franzke A, Schrader A, Patzelt T, et al. Capecitabine in the treatment of metastatic renal cell carcinoma. Br J Cancer. 2000 Sep;83(5):583-7.; Wenzel C, Locker GJ, Schmidinger M, Mader R, Kramer G, Marberger M, et al. Capecitabine in the treatment of metastatic renal cell carcinoma failing immunotherapy. Am J Kidney Dis. 2002 Jan;39(1):48-54.; https://www.malignanttumors.org/jour/article/view/143

Διαθεσιμότητα: https://www.malignanttumors.org/jour/article/view/143
https://doi.org/10.18027/2224-5057-2011-1-40-44

View record from BASE

12

Academic Journal